ACRS实时信号 | 通过Getagraph.com最大化利润

购买 107900 min ago

@ $1.220

发出时间: 14 Feb 2024 @ 23:55

回报率: 0.00%

上一信号: Feb 14 - 22:47

上一信号: 出售

回报率: 0.00 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 22:16):

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States...

Stats
今日成交量	46 510.00
平均成交量	1.08M
市值	86.94M
EPS	$-0.0200 ( 2024-02-29 )
下一个收益日期	( $-0.340 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.960
ATR14	$0.00600 (0.49%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Walker Neal	Buy	9 467	Common Stock
2024-04-01	Walker Neal	Sell	3 224	Common Stock
2024-04-01	Walker Neal	Sell	9 467	Restricted Stock Units
2024-03-01	Walker Neal	Buy	9 466	Common Stock
2024-03-01	Walker Neal	Sell	3 223	Common Stock

INSIDER POWER
77.37
Last 99 transactions
Buy: 2 297 521 \| Sell: 311 390

音量相关性

長: -0.04 (neutral)

短: 0.00 (neutral)

Signal:(66.724) Neutral

Aclaris Therapeutics Inc 相关性

10 最正相关
POET	0.958
AACG	0.946
GETVV	0.946
AVIR	0.946
NAKD	0.945
HLIO	0.944
IMPL	0.944
CRTO	0.944
HTCR	0.941
CMMB	0.94

10 最负相关
IDCC	-0.95
MPRA	-0.949
TZPSU	-0.947
CEG	-0.945
SLMBP	-0.945
STRA	-0.944
GALT	-0.944
CALB	-0.943
PRAA	-0.942
MEOH	-0.941

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Aclaris Therapeutics Inc 相关性 - 货币/商品

-0.71
( moderate negative )

-0.67
( moderate negative )

0.00
( neutral )

0.03
( neutral )

Aclaris Therapeutics Inc 财务报表

Annual	2023
营收:	$31.25M
毛利润:	$13.17M (42.14 %)
EPS:	$-1.270

FY	2023
营收:	$31.25M
毛利润:	$13.17M (42.14 %)
EPS:	$-1.270

FY	2022
营收:	$29.75M
毛利润:	$17.79M (59.80 %)
EPS:	$-1.360

FY	2021
营收:	$6.76M
毛利润:	$2.05M (30.29 %)
EPS:	$-2.14

Financial Reports:

No articles found.

Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.